Literature DB >> 15611270

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Jenni M Vuola1, Sheila Keating, Daniel P Webster, Tamara Berthoud, Susanna Dunachie, Sarah C Gilbert, Adrian V S Hill.   

Abstract

Heterologous prime-boost vaccination has been shown to be an efficient way of inducing T cell responses in animals and in humans. We have used three vaccine vectors, naked DNA, modified vaccinia virus Ankara (MVA), and attenuated fowlpox strain, FP9, for prime-boost vaccination approaches against Plasmodium falciparum malaria in humans. In this study, we characterize, using two types of ELISPOT assays and FACS analysis, cell-mediated immune responses induced by different prime-boost combinations where all vectors encode a multiepitope string fused to the pre-erythrocytic Ag thrombospondin-related adhesion protein. We show that these different vectors need to be used in a specific order for an optimal ex vivo IFN-gamma response. From the different combinations, DNA priming followed by MVA boosting and FP9 priming followed by MVA boosting were most immunogenic and in both cases the IFN-gamma response was of broad specificity and cross-reactive against two P. falciparum strains (3D7 and T9/96). Immunization with all three vectors showed no improvement over optimal two vector regimes. Strong ex vivo IFN-gamma responses peaked 1 wk after the booster dose, but cultured ELISPOT assays revealed longer-lasting T cell memory responses for at least 6 mo. In the DNA-primed vaccinees the IFN-gamma response was mainly due to CD4(+) T cells, whereas in the FP9-primed vaccinees it was mainly due to CD4-dependent CD8(+) T cells. This difference may be of importance for the protective efficacy of these vaccination approaches against various diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15611270     DOI: 10.4049/jimmunol.174.1.449

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

Review 1.  Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors:  Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal:  Clin Immunol       Date:  2010-12-24       Impact factor: 3.969

Review 2.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

3.  Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.

Authors:  Michael Walther; Fiona M Thompson; Susanna Dunachie; Sheila Keating; Stephen Todryk; Tamara Berthoud; Laura Andrews; Rikke F Andersen; Anne Moore; Sarah C Gilbert; Ian Poulton; Filip Dubovsky; Eveline Tierney; Simon Correa; Angela Huntcooke; Geoffrey Butcher; Jack Williams; Robert E Sinden; Adrian V S Hill
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 4.  Viral vector vaccines make memory T cells against malaria.

Authors:  Arturo Reyes-Sandoval; John T Harty; Stephen M Todryk
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

Review 5.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

6.  IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine.

Authors:  Sandra A Calarota; Anlan Dai; Jeffrey N Trocio; David B Weiner; Franco Lori; Julianna Lisziewicz
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

Review 7.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

Review 8.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

9.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

10.  Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Authors:  Mark J Cayabyab; Birgit Korioth-Schmitz; Yue Sun; Angela Carville; Harikrishnan Balachandran; Ayako Miura; Kevin R Carlson; Adam P Buzby; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.